OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided

Authors: Dirk Arnold, Andres Cervantes, Michel Pierre Ducreux, Sae-Won Han, Heinz-Josef Lenz, Kei Muro, Kanwal Pratap Singh Raghav, Lin Shen, Chao-Yuan Wang, Pei Jye Voon, Hung-Chih Hsu, Bing Xia, Ryota Iwasawa, Shamita Carrigan, Brooke Diorio, Patricia A. Lorenzini, Sandip Acharya, Seema Niphadkar Sethi, Mahadi Baig, Filippo Pietrantonio

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3636

Source: Full article

---

Abstract

TPS3636